Patents by Inventor Oz Scott Halpern
Oz Scott Halpern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932658Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and Ri, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: GrantFiled: January 6, 2021Date of Patent: March 19, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
-
Publication number: 20230045357Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.Type: ApplicationFiled: July 11, 2022Publication date: February 9, 2023Applicants: Université de Montréal, Bristol-Myers Squibb CompanyInventors: Eldon Scott PRIESTLEY, Samuel Kaye REZNIK, Edward H. RUEDIGER, James R. GILLARD, Oz Scott HALPERN, Wen JIANG, Jeremy RICHTER, Rejean RUEL, Sasmita TRIPATHY, Wu YANG, Xiaojun ZHANG
-
Patent number: 11407733Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.Type: GrantFiled: June 28, 2017Date of Patent: August 9, 2022Assignees: Bristol-Myers Squibb CompanyInventors: Eldon Scott Priestley, Samuel Kaye Reznik, Edward H. Ruediger, James R. Gillard, Oz Scott Halpern, Wen Jiang, Jeremy Richter, Rejean Ruel, Sasmita Tripathy, Wu Yang, Xiaojun Zhang
-
Patent number: 11059818Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.Type: GrantFiled: March 10, 2017Date of Patent: July 13, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Joanne M. Smallheer, Carol Hui Hu, Meriah Neissel Valente, Scott A. Shaw, Benjamin P. Vokits, Oz Scott Halpern
-
Publication number: 20210188877Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: ApplicationFiled: January 6, 2021Publication date: June 24, 2021Inventors: Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
-
Publication number: 20210163465Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: ApplicationFiled: December 16, 2020Publication date: June 3, 2021Inventors: Xiaojun Zhang, Eldon Scott Priestley, J. Alex Bates, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
-
Publication number: 20200291015Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.Type: ApplicationFiled: March 10, 2017Publication date: September 17, 2020Inventors: Joanne M. Smallheer, Carol Hui HU, Meriah Neissel Valente, Scott A. Shaw, Benjamin P. Vokits, Oz Scott Halpern
-
Patent number: 10730868Abstract: Disclosed are compounds of Formula (I) to (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: GrantFiled: July 13, 2017Date of Patent: August 4, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Qinghong Fu, Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
-
Patent number: 10577383Abstract: The present invention provides compounds of Formula (I): wherein the substituents are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.Type: GrantFiled: June 26, 2017Date of Patent: March 3, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Joanne M. Smallheer, Ellen K. Kick, Meriah Neissel Valente, Carol Hui Hu, Oz Scott Halpern, Sutjano Jusuf
-
Publication number: 20190315774Abstract: Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: ApplicationFiled: July 13, 2017Publication date: October 17, 2019Inventors: XIAOJUN Zhang, Eldon Scott Priestley, Oz Scott Halpern, Wen Jiang, Samuel Kaye Reznik, Jeremy M. Richter
-
Publication number: 20190300520Abstract: Disclosed are compounds of Formula (I) to (IV): [INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: ApplicationFiled: July 13, 2017Publication date: October 3, 2019Inventors: Qinghong Fu, Xiaojun Zhang, Eldon Scott Priestley, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
-
Publication number: 20190292176Abstract: Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.Type: ApplicationFiled: July 13, 2017Publication date: September 26, 2019Inventors: Xiaojun Zhang, Eldon Scott Priestley, J. Alex Bates, Oz Scott Halpern, Samuel Kaye Reznik, Jeremy M. Richter
-
Patent number: 10407422Abstract: The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.Type: GrantFiled: August 30, 2016Date of Patent: September 10, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Joanne M. Smallheer, Scott A. Shaw, Oz Scott Halpern, Carol Hui Hu, Ellen K. Kick
-
Publication number: 20190202808Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.Type: ApplicationFiled: June 28, 2017Publication date: July 4, 2019Inventors: Eldon Scott PRIESTLEY, Samuel Kaye REZNIK, Edward H. RUEDIGER, James R. GILLARD, Oz Scott HALPERN, Wen JIANG, Jeremy RICHTER, Rejean RUEL, Sasmita TRIPATHY, Wu YANG, Xiaojun ZHANG
-
Publication number: 20190177340Abstract: The present invention provides compounds of Formula (I): wherein the substituents are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.Type: ApplicationFiled: June 26, 2017Publication date: June 13, 2019Inventors: Joanne M. Smallheer, Ellen K. Kick, Meriah Neissel Valente, Carol Hui Hu, Oz Scott Halpern, Sutjano Jusuf
-
Publication number: 20190023701Abstract: The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.Type: ApplicationFiled: August 30, 2016Publication date: January 24, 2019Inventors: Joanne M. Smallheer, Scott A. Shaw, Oz Scott Halpern, Carol Hui Hu, Ellen K. Kick